InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Neumora Therapeutics, Inc.

NMRA Clue Score40
United States Fiscal year ends December CIK 0001885522
$0.48 -0.85% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.48 −96.02% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 14 Sep 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2022Operating income−135.9Net income−130.9EPS, diluted−4.81Fiscal year 2023Operating income−252.1Net income−235.9EPS, diluted−3.63Fiscal year 2024Operating income−263.5Net income−243.8EPS, diluted−1.53Fiscal year 2025Operating income−241.2Net income−236.9EPS, diluted−1.45
FY2022FY2023FY2024FY2025
Operating income −135.9 −252.1 −263.5 −241.2
Net income −130.9 −235.9 −243.8 −236.9
Growth
EPS, diluted −4.81 −3.63 −1.53 −1.45

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−114.9Capital expenditure−0.5Free cash flow−115.4Fiscal year 2023Operating cash flow−163.3Capital expenditure−0.1Free cash flow−163.4Fiscal year 2024Operating cash flow−182.9Fiscal year 2025Operating cash flow−206.4
FY2022FY2023FY2024FY2025
Operating cash flow −114.9 −163.3 −182.9 −206.4
Capital expenditure −0.5 −0.1 n/a n/a
Free cash flow −115.4 −163.4 n/a n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2022Cash240.9Shareholders’ equity−446.9Fiscal year 2023Cash374.0Shareholders’ equity469.1Fiscal year 2024Cash142.1Total debt0.0Net cash (debt)142.1Shareholders’ equity287.1Debt to equity0.00Fiscal year 2025Cash182.5Total debt114.5Net cash (debt)68.0Shareholders’ equity103.9Debt to equity1.10
FY2022FY2023FY2024FY2025
Cash 240.9 374.0 142.1 182.5
Total debt n/a n/a 0.0 114.5
Net cash (debt) n/a n/a 142.1 68.0
Shareholders’ equity −446.9 469.1 287.1 103.9
Debt to equity n/a n/a 0.00 1.10

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −50.3% −84.9% −228.1%
−30.7% −47.5% −76.9% −124.0%
Balance and payout
n/a n/a 0.00 1.10
6.9% 5.5% 9.4% 45.6%